No Data
No Data
The Nikkei average started 95 yen higher, with KOKUSAI, Mercari, and others rising.
[Nikkei Average Stock Price and TOPIX (Table)] Nikkei Average; 41009.36; + 95.71 TOPIX; 2900.18; + 1.71 [Opening Summary] On the 5th, the Nikkei Average opened with a 6th consecutive increase of 95.71 yen to 41009.36 yen. On the previous day, the US market on the 4th was closed for Independence Day. In Europe, the UK's FTSE TM100 rose by 0.86%, Germany's DAX rose by 0.41%, and France's CAC40 rose by 0.83%. Today's Tokyo stock market started with buying. Yesterday's US stock market.
Speee, Astellas Pharma, etc. (Part 2)
<4499> Speee Inc. Rakuten Securities, Inc. shareholding ratio: 5.08% → 0.51%. Reporting obligation date: June 28, 2024.<4503> Astellas Pharma Inc. BlackRock Japan Co., Ltd. shareholding ratio: 8.52% → 7.50%. Reporting obligation date: June 28, 2024.<4674> Cresco Ltd. Iwasaki Corporation shareholding ratio: 20.36% → 20.36%.
China's National Medical Products Administration approved the new indication of Enzalutamide (XTANDI) for the treatment of metastatic hormone-sensitive prostate cancer.
This is the third indication for advanced prostate cancer treatment approved by Enzalutamide in China. Approval is based on positive results from the global and China ARCHES phase III studies. Compared to placebo combined with androgen deprivation therapy (ADT), Enzalutamide combined with ADT significantly delayed progression time of prostate specific antigen (PSA). Tokyo, July 2, 2024 /PRNewswire/ - Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") announced today that the National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved an indication extension for XTANDI® (Enzalutamide) capsules to treat adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in China.
Astellas Pharma: Extraordinary Report
Nikkei average contribution ranking (pre-market) - Nikkei average continues to rise, pushed up by about 50 yen with two stocks, SoftBank G and KDDI corporation.
As of the close of July 1st, the number of rising stocks among the Nikkei average constituent stocks was 153, the number of falling stocks was 72, and the number of unchanged stocks was 0. The Nikkei average continued to rise. It ended the morning session with a trading volume of approximately 820 million shares and a 104.32 yen increase (+0.26%) compared to the previous business day, closing at 39,687.40 yen. The US stock market on the 28th fell. The Dow Jones Industrial Average was down 45.20 points (-0.12%) to 39,118.86, and the NASDAQ Index was down 126.08 points (-0.71%) to 17,732.
Nikkei Stock Average contribution ranking (pre-closing) - Nikkei Stock Average rebounded, SoftBank Group pushed up about 63 yen with one stock.
As of the closing time 28 days ago, the number of rising stocks in the Nikkei Average constituent stocks was 158, the number of falling stocks was 63, and the number of unchanged stocks was 4. The Nikkei Average rebounded. It ended the morning session at 39,727.91 yen (with an approximate trading volume of 800 million shares), up 386.37 yen (+0.98%) from the previous day. The U.S. stock market on the 27th continued to rise slightly. The Dow Jones Industrial Average was up 36.26 points (+0.09%) at 39,164.06 and the Nasdaq composite closed at 17,858.68, up 53.53 points (+0.30%). S&P.
No Data